Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers
Authors:
Open Access
- 24 June 2015
- journal article
- review article
- Published by Wiley in Respirology
- Vol. 20 (7) , 1010-1022
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic lung disease associated with high morbidity and poor survival. Characterized by substantial disease heterogeneity, the diagnostic considerations, clinical course and treatment response in individual patients can be variable. In the past decade, with the advent of high‐throughput proteomic and genomic technologies, our understanding of the pathogenesis of IPF has greatly improved and has led to the recognition of novel treatment targets and numerous putative biomarkers. Molecular biomarkers with mechanistic plausibility are highly desired in IPF, where they have the potential to accelerate drug development, facilitate early detection in susceptible individuals, improve prognostic accuracy and inform treatment recommendations. Although the search for candidate biomarkers remains in its infancy, attractive targets such as MUC5B and MPP7 have already been validated in large cohorts and have demonstrated their potential to improve clinical predictors beyond that of routine clinical practices. The discovery and implementation of future biomarkers will face many challenges, but with strong collaborative efforts among scientists, clinicians and the industry the ultimate goal of personalized medicine may be realized.Keywords
Funding Information
- Canadian Institute for Health Research
- Canadian Pulmonary Fibrosis Foundation
- Pulmonary Fibrosis Foundation
This publication has 130 references indexed in Scilit:
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Endoplasmic reticulum stress enhances fibrotic remodeling in the lungsProceedings of the National Academy of Sciences, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- A CommonMUC5BPromoter Polymorphism and Pulmonary FibrosisNew England Journal of Medicine, 2011
- Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthmaProceedings of the National Academy of Sciences, 2010
- Surfactant Protein A2 Mutations Associated with Pulmonary Fibrosis Lead to Protein Instability and Endoplasmic Reticulum StressJournal of Biological Chemistry, 2010
- Short telomeres are a risk factor for idiopathic pulmonary fibrosisProceedings of the National Academy of Sciences, 2008
- Adult-onset pulmonary fibrosis caused by mutations in telomeraseProceedings of the National Academy of Sciences, 2007
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001